Long awaited data from the clinical investigation of bladder cancer in both the neoadjuvant and adjuvant settings were released in 2011, setting the stage for the next generation of work in this area. The findings of a number of studies provide the first steps towards a personalized approach to this disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hahn, N. M. et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75. J. Clin. Oncol. 29, 1525–1530 (2011).
Said, N., Smith, S., Sanchez-Carbayo, M. & Theodorescu, D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 121, 132–147 (2011).
Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).
Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
Smith, S. C. et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 12, 137–143 (2011).
Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875–878 (2011).
Esrig, D. et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331, 1259–1264 (1994).
Ferreira, C. G., Tolis, C. & Giaccone, G. p53 and chemosensitivity. Ann. Oncol. 10, 1011–1021 (1999).
Stadler, W. M. et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29, 3443–3449 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Theodorescu declares that is a patent holder or applicant for the University of Colorado. T. W. Flaig declares no competing interests.
Rights and permissions
About this article
Cite this article
Flaig, T., Theodorescu, D. The dawn of personalized medicine. Nat Rev Urol 9, 65–66 (2012). https://doi.org/10.1038/nrurol.2011.220
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.220
This article is cited by
-
The importance of personalized medicine in urological cancers
Journal of Diabetes & Metabolic Disorders (2022)